Financial reports
10-Q
2022 Q1
Quarterly report
27 Apr 22
10-K
2021 FY
Annual report
3 Mar 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
10-Q
2021 Q2
Quarterly report
12 Aug 21
10-Q
2021 Q1
Quarterly report
5 May 21
10-K/A
2020 FY
Annual report (amended)
30 Apr 21
10-K
2020 FY
Annual report
23 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
Current reports
8-K
Termination of a Material Definitive Agreement
11 Jul 22
8-K
Innoviva to Acquire Entasis Therapeutics
23 May 22
8-K
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
27 Apr 22
8-K
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
3 Mar 22
8-K
Departure of Directors or Certain Officers
25 Feb 22
8-K
Entry into a Material Definitive Agreement
18 Feb 22
8-K
Departure of Directors or Certain Officers
14 Jan 22
8-K
Departure of Directors or Certain Officers
12 Nov 21
8-K
Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
4 Nov 21
8-K
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
19 Oct 21
Registration and prospectus
15-12G
Securities registration termination
21 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
POS AM
Prospectus update (post-effective amendment)
11 Jul 22
POS AM
Prospectus update (post-effective amendment)
11 Jul 22
POS AM
Prospectus update (post-effective amendment)
11 Jul 22
Proxies
DEF 14A
Definitive proxy
17 May 21
DEFA14A
Additional proxy soliciting materials
17 May 21
PRE 14A
Preliminary proxy
5 May 21
DEFA14A
Additional proxy soliciting materials
3 May 21
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEF 14A
Definitive proxy
15 May 20
PRE 14A
Preliminary proxy
5 May 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
Other
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
6 Aug 21
CORRESP
Correspondence with SEC
3 Aug 21
UPLOAD
Letter from SEC
3 Aug 21
EFFECT
Notice of effectiveness
14 Oct 20
CORRESP
Correspondence with SEC
9 Oct 20
UPLOAD
Letter from SEC
8 Oct 20
Ownership
4
Change in insider ownership
13 Jul 22
SC 13D/A
Innoviva, Inc.
11 Jul 22
4
Kristie Ann Wagner
11 Jul 22
4
Anna Diaz Triola
11 Jul 22
4
Ruben Tommasi
11 Jul 22
4
Matthew Ronsheim
11 Jul 22
4
Manoussos Perros
11 Jul 22
4
John Patrick Mueller
11 Jul 22
4
David D. Meek
11 Jul 22
4
Howard Mayer
11 Jul 22